[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05174351":3,"trial-entities:NCT05174351":96,"trial-summary:NCT05174351":101},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":25,"primary_purpose":26,"phases":27,"enrollment_info":29,"interventions":32,"primary_outcomes":37,"secondary_outcomes":42,"sex":52,"minimum_age":53,"maximum_age":54,"healthy_volunteers":15,"eligibility_criteria":55,"std_ages":69,"locations":72,"central_contacts":88,"overall_officials":91,"references":94,"see_also_links":95},"NCT05174351","22-145-2","Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction","Effect of Beta-blocker Discontinuation on Functional Capacity and Cardiac Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction","RECRUITING","2027-11-01","2025-07","2025-09-29","2021-12-20","UConn Health","OTHER",false,"This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.","This is a prospective pilot study to evaluate changes before and 4 weeks(+\u002F- 1 week) after beta-blocker withdrawal in 30 HFpEF patients. The study involves 2 visits that are 4 weeks apart. The first study visit will occur at a standard of care clinic visit and the second visit will be a research visit to fill out questionnaires and perform the limited echocardiogram. No long term follow up beyond the 2nd visit.",[19],"Heart Failure With Preserved Ejection Fraction",[21,22,23,24],"HFpEF","Beta-blocker","echocardiogram","6MWT","INTERVENTIONAL","TREATMENT",[28],"NA",{"count":30,"type":31},30,"ESTIMATED",[33],{"type":14,"name":34,"description":34,"armGroupLabels":35},"beta blocker discontinuation",[36],"HFpEF patients",[38],{"measure":39,"description":40,"timeFrame":41},"Changes in KCCQ-23 score","Kansa city cardiomyopathy questionnaire (KCCQ-23)- self-administered, 23-item. questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life. Scores are transformed to a range of 0-100, where higher scores reflect better health status.","Baseline and after 4 weeks of beta blocker discontinuation",[43,46,49],{"measure":44,"description":45,"timeFrame":41},"Changes in cardiac mechanics by echocardiography","Echocardiographic E\u002Fe' ratio",{"measure":47,"description":48,"timeFrame":41},"Changes in biomarker","changes from baseline in BNP level (pg\u002FmL) after 4 weeks of beta blocker discontinuation",{"measure":50,"description":51,"timeFrame":41},"6 minute walk test","The distance (meters) covered over a time of 6 minutes. A greater distance indicates a better exercise capacity.","ALL","50 Years","80 Years",{"inclusion":56,"exclusion":63,"raw_text":68},[57,58,59,60,61,62],"Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100","N=30 (Target: 30).","Age: 50 \\~ 80 years.","ECHO evidence of EF ≥50% and Grade 2 or 3 diastolic dysfunction.","Chronic loop diuretic use","Currently on beta-blocker",[64,65,66,67],"Beta blocker was prescribed for treating other cardiac conditions such as atrial fibrillation or coronary artery disease.","Heart rate \\> 100 bpm","Recent hospitalization due to HF within 3 months","Non-English speaker","Inclusion Criteria:\n\n* Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100\n* N=30 (Target: 30).\n* Age: 50 \\~ 80 years.\n* ECHO evidence of EF ≥50% and Grade 2 or 3 diastolic dysfunction.\n* Chronic loop diuretic use\n* Currently on beta-blocker\n\nExclusion Criteria:\n\n* Beta blocker was prescribed for treating other cardiac conditions such as atrial fibrillation or coronary artery disease.\n* Heart rate \\> 100 bpm\n* Recent hospitalization due to HF within 3 months\n* Non-English speaker",[70,71],"ADULT","OLDER_ADULT",[73],{"facility":74,"status":8,"city":75,"state":76,"zip":77,"country":78,"contacts":79,"geoPoint":85},"UConn Health \u002F John Dempsey Hospital","Farmington","Connecticut","06030","United States",[80],{"name":81,"role":82,"phone":83,"email":84},"Kai Chen, MD, PhD","CONTACT","860-679-3343","kachen@uchc.edu",{"lat":86,"lon":87},41.71982,-72.83204,[89],{"name":90,"role":82,"phone":83,"email":84},"Kai Chen, MD,PhD",[92],{"name":90,"affiliation":13,"role":93},"PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":97,"biomarkers":99},[98],"Heart failure with normal ejection fraction",[100],"NPPB wt Allele",{"nct_id":4,"found":102,"summary":103,"prompt_version":112},true,{"design":104,"status":105,"heading":6,"summary":106,"follow_up":107,"word_count":108,"commitments":109,"compensation":110,"drugs_mentioned":111},"This is a pilot study that will look at changes in 30 participants before and after stopping beta-blockers. It is an interventional study, meaning participants will receive a specific intervention.","completed","This study is looking at what happens when people with a type of heart failure called Heart Failure With Preserved Ejection Fraction (HFpEF) stop taking their beta-blocker medication. Researchers want to see if stopping beta-blockers changes how you feel and your quality of life. They will measure this using a questionnaire called the KCCQ-23 score. You might be able to join if you are between 50 and 80 years old, have stable HFpEF, and are currently taking a beta-blocker. The study aims to enroll 30 participants, but its current recruitment status is unclear.","There is no long-term follow-up beyond the second visit, which occurs 4 weeks after stopping beta-blockers.",93,"You would have two study visits over a period of about 4 weeks. The first visit is a standard clinic visit, and the second involves questionnaires and a limited echocardiogram (a heart ultrasound).","Not stated in the trial record.",[],"v2"]